Compare FLOC & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLOC | MRVI |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 509.0M | 472.8M |
| IPO Year | 2025 | 2020 |
| Metric | FLOC | MRVI |
|---|---|---|
| Price | $22.61 | $3.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $29.00 | $4.57 |
| AVG Volume (30 Days) | 257.9K | ★ 1.1M |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $748,499,000.00 | $192,435,000.00 |
| Revenue This Year | $43.28 | N/A |
| Revenue Next Year | $12.09 | $10.00 |
| P/E Ratio | $16.62 | ★ N/A |
| Revenue Growth | ★ 76.22 | N/A |
| 52 Week Low | $14.03 | $1.67 |
| 52 Week High | $29.14 | $5.03 |
| Indicator | FLOC | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 65.49 | 35.12 |
| Support Level | $20.85 | $3.30 |
| Resistance Level | $23.23 | $3.51 |
| Average True Range (ATR) | 1.08 | 0.18 |
| MACD | 0.13 | -0.07 |
| Stochastic Oscillator | 82.81 | 7.49 |
Flowco Holdings Inc is a provider of production optimization, artificial lift and methane abatement solutions for the oil and natural gas industry. Its technologies include high pressure gas lift (HPGL), conventional gas lift, plunger lift and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions which include rental services and Natural Gas Technologies which include service gas compression parts and equipment sales. Production Solutions: relates to rentals, sales and services related to high pressure gas lift, conventional gas lift and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.